🔍

MARKSANS - Marksans Pharma

📊 NSE: MARKSANS 🏢 Pharmaceuticals - Indian - Formulations 📅 Last Updated: 12/14/2025 9:37

📢 Recent Corporate Announcements

Marksans Pharma Opens Special Window for Physical Share Transfer Re-lodgment until Feb 2027

🟡 NEUTRAL ⭐ 3/10

REGULATORY 📅 11 Mar 2026, 04:34 PM

Marksans Pharma has announced a one-year special window for shareholders to re-lodge transfer requests for physical shares purchased before April 1, 2019. This initiative follows a SEBI circular aimed at resolving pending transfer issues caused by document deficiencies. The window is active from February 5, 2026, to February 4, 2027. Successfully transferred shares will be credited directly to demat accounts and will be subject to a mandatory one-year lock-in period.

Special window open for one year from February 5, 2026, to February 4, 2027
Applies to shares purchased or sold prior to April 1, 2019, that were previously rejected
Transferred shares will be credited in demat mode only with no physical certificates issued
Mandatory one-year lock-in period applies to all shares registered through this special window
Excludes shares involved in legal disputes or those already transferred to the IEPF

💡 Shareholders holding physical shares with pending transfer issues should contact Bigshare Services Pvt Ltd before the February 2027 deadline. General investors can treat this as a routine regulatory update with no impact on company valuation.

Marksans Pharma to Attend Investec India Promoter & Founder Conference 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Mar 2026, 04:54 PM

Marksans Pharma has announced that its officials will participate in the Investec India Promoter & Founder Conference 2026. The event is scheduled for March 11, 2026, at 11:00 AM IST and will be held physically at Trident BKC, Mumbai. The company has explicitly stated that no unpublished price-sensitive information (UPSI) will be discussed during this interaction. This disclosure is a routine regulatory requirement under SEBI Listing Regulations to inform shareholders about management's engagement with institutional investors.

Participation in the Investec India Promoter & Founder Conference 2026 on March 11, 2026
Physical meeting format at Trident BKC, Mumbai starting at 11:00 AM IST
Company confirms no unpublished price-sensitive information (UPSI) will be shared
Compliance filing under Regulation 30(6) of the SEBI Listing Regulations

💡 No immediate action is required as this is a routine investor relations event. Investors may monitor for any post-conference presentations or transcripts for updates on the company's outlook.

Marksans Pharma Q3 FY26 Revenue Hits Record INR 754 Cr; EBITDA Margins Expand to 21.3%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 12 Feb 2026, 04:07 PM

Marksans Pharma reported a resilient Q3 FY26 with record operating revenue of INR 754.4 crores, a 10.6% YoY increase driven by strong US performance and seasonal demand. EBITDA margins expanded significantly by 217 bps to 21.3% due to operating leverage and softening raw material costs. The company remains debt-free with a robust cash balance of INR 824.2 crores and a strong US order book exceeding $220 million. Management is actively pursuing global expansion through new subsidiaries in Europe and Canada while targeting a long-term revenue milestone of INR 4,000 crores.

Q3 FY26 revenue grew 10.6% YoY to an all-time high of INR 754.4 crores.
EBITDA increased 23.2% YoY to INR 160.7 crores with margins expanding to 21.3%.
US and North American markets grew 16.9% YoY, supported by a $220 million+ order book.
The company remains debt-free with a cash surplus of INR 824.2 crores as of December 2025.
Teva facility utilization is improving, currently contributing INR 560-600 crores toward an INR 800 crore target.

💡 Investors should view the margin expansion and strong US order book as positive indicators of operational efficiency. The company's debt-free status and significant cash reserves provide a strong cushion for its planned M&A and international expansion.

Marksans Pharma Releases Q3 & 9M FY26 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 06 Feb 2026, 06:35 PM

Marksans Pharma has officially released the audio recording of its investor and analyst conference call held on February 06, 2026. The call addressed the company's financial performance for the third quarter and the nine-month period of FY26. This disclosure is a standard regulatory requirement under SEBI (LODR) Regulations to ensure all investors have access to management commentary. Shareholders can access the recording through the company's website to evaluate the business outlook discussed during the session.

Audio recording of the Q3 & 9M FY26 earnings call was uploaded on February 06, 2026.
The call involved discussions with institutional investors and analysts regarding recent financial results.
Compliance filing made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Direct access provided via the company's official earnings call transcripts web page.

💡 Investors should listen to the recording to gain insights into management's perspective on market share gains in the UK and US. It is advisable to wait for the written transcript for a detailed analysis of specific financial queries raised by analysts.

Marksans Pharma Releases Audio Recording of Q3 & 9M FY26 Earnings Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 06:29 PM

Marksans Pharma Limited has officially uploaded the audio recording of its investor and analyst conference call for the Q3 and 9M FY26 financial results. The call was conducted on February 06, 2026, following the disclosure of the company's periodic financial performance. This filing is a mandatory compliance requirement under Regulation 30 of the SEBI (LODR) Regulations, 2015. Investors can access the recording on the company's website to gain insights into management's commentary on the business outlook.

Audio recording of the Q3 & 9M FY26 earnings call is now available for public access.
The conference call was held on February 06, 2026, to discuss the nine-month performance of the fiscal year.
Compliance maintained under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The recording is hosted on the company's official website under the earnings call transcripts section.

💡 Investors should listen to the recording to understand management's guidance on future growth and operational challenges. This is a routine procedural update and does not require immediate action.

Marksans Pharma Q3 FY26: Revenue Up 10.6% YoY to ₹754.4 Cr, EBITDA Margin Hits 21.3%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 02:05 PM

Marksans Pharma reported a resilient Q3 FY26 with operating revenue growing 10.6% YoY to ₹754.4 crore, driven by strong volume growth in the US and Australia markets. EBITDA grew significantly by 23.2% YoY to ₹160.7 crore, with margins expanding by 217 bps to 21.3% due to favorable raw material costs and currency tailwinds. While quarterly PAT rose 8.2% YoY to ₹113.7 crore, the nine-month PAT remains down 7.1% YoY at ₹271.0 crore. The company maintains a robust cash balance of ₹824.2 crore and is expanding its global footprint with new subsidiaries in Europe and Canada.

Operating revenue increased 10.6% YoY to ₹754.4 cr, with US market revenue growing 16.9% to ₹412.4 cr.
EBITDA rose 23.2% YoY to ₹160.7 cr, with EBITDA margins expanding 217 bps YoY to 21.3%.
Quarterly PAT grew 8.2% YoY to ₹113.7 cr, though 9MFY26 PAT is down 7.1% YoY at ₹271.0 cr.
Strong cash position of ₹824.2 cr as of December 31, 2025, with ₹263.2 cr cash generated from operations in 9MFY26.
Australia and New Zealand business reported robust growth of 30.1% YoY, reaching ₹61.4 cr.

💡 Investors should monitor the sustainability of the 21% EBITDA margins and the progress of the new European and Canadian subsidiaries. The strong cash position and recovery in quarterly PAT suggest a positive trend despite a weaker 9-month performance.

Marksans Pharma Q3 FY26: Revenue Up 10.6% to ₹754 Cr, EBITDA Margins Expand to 21.3%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 01:54 PM

Marksans Pharma reported a resilient Q3 FY26 performance with operating revenue growing 10.6% YoY to ₹754.4 crore. EBITDA saw a significant jump of 23.2% YoY to ₹160.7 crore, with margins expanding to 21.3% due to soft raw material costs and favorable currency movements. The US market led growth with a 16.9% YoY increase, while the company maintained a strong cash position of ₹824.2 crore. Despite a soft Q1, the 9M FY26 trajectory shows recovery with profitability improving meaningfully in the recent quarters.

Q3 FY26 Revenue grew 10.6% YoY to ₹754.4 cr and PAT rose 8.2% YoY to ₹113.7 cr
EBITDA margins expanded 220 bps YoY to 21.3%, driven by operating leverage and product mix
US & North America revenue reached ₹412.4 cr, up 16.9% YoY, aided by winter seasonality
Cash balance remains strong at ₹824.2 cr with 9M FY26 operating cash flow of ₹263.2 cr
R&D investment for 9M FY26 stood at ₹62.0 cr, representing 3.0% of consolidated revenue

💡 The stock remains a positive play on the OTC segment growth in regulated markets like the US and UK. Investors should monitor the integration of the new Goa facility which is expected to double capacity and drive future volume growth.

Marksans Pharma Q3 PAT Surges 192% YoY to ₹609.11 Million; Revenue Up 38%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 05 Feb 2026, 01:36 PM

Marksans Pharma reported a stellar performance for Q3 FY26, with consolidated revenue from operations growing 38.3% YoY to ₹3,597.20 million. Net profit (PAT) witnessed a massive jump of 192% YoY, reaching ₹609.11 million compared to ₹208.41 million in the same period last year. The company is actively pursuing global expansion, having incorporated new subsidiaries in Ireland and Canada in January 2026. Despite a one-time impact of ₹28.10 million from new labour code provisions, the company's operational efficiency remains high with an EPS of ₹1.34.

Revenue from operations grew 38.3% YoY to ₹3,597.20 million in Q3 FY26.
Net Profit (PAT) increased significantly to ₹609.11 million from ₹208.41 million in the year-ago period.
Earnings Per Share (EPS) rose to ₹1.34 for the quarter, up from ₹0.46 in Q3 FY25.
Incorporated two new wholly-owned subsidiaries in Ireland and Canada in January 2026 to drive international expansion.
Accounted for a ₹28.10 million incremental impact due to the implementation of New Labour Codes.

💡 Investors should take note of the strong triple-digit profit growth and aggressive international expansion. The stock remains a positive prospect for long-term investors given the consistent improvement in margins and global footprint.

Marksans Pharma Incorporates Two New Wholly Owned Subsidiaries in Ireland and Canada

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 27 Jan 2026, 02:16 PM

Marksans Pharma Limited has expanded its global footprint by incorporating two new wholly owned subsidiaries: Marksans Pharma (Europe) Limited in Ireland and Marksans (Canada) Inc. in Canada. Both entities are established to carry out the business of pharmaceutical products in their respective regions. While these are newly formed entities with no immediate turnover, they represent a strategic move to strengthen the company's direct presence in the European and North American markets. This expansion aligns with the company's long-term growth strategy to scale its international operations.

Incorporation of Marksans Pharma (Europe) Limited as a 100% subsidiary in Ireland.
Incorporation of Marksans (Canada) Inc. as a 100% subsidiary in Canada.
Both subsidiaries are dedicated to the pharmaceutical products business segment.
The entities are newly incorporated with no prior history of turnover or size.
Move aimed at enhancing market penetration in the European and Canadian pharmaceutical sectors.

💡 Investors should monitor these developments as they indicate the company's intent to scale international operations. No immediate action is required, but look for future revenue contributions from these regions in upcoming fiscal years.

Marksans Pharma Schedules Q3FY26 Earnings Conference Call for February 6, 2026

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 22 Jan 2026, 04:43 PM

Marksans Pharma Limited has announced its earnings conference call for the third quarter and nine months ended December 31, 2025, scheduled for February 6, 2026, at 4:00 PM IST. The management team, including the Founder & CMD Mark Saldanha and CFO Jitendra Sharma, will discuss the company's unaudited financial results. This call is a standard procedure following the release of quarterly results to provide clarity on performance and future strategy. Investors can access the call through provided universal dial-in numbers or the Diamond Pass link.

Conference call scheduled for Friday, February 6, 2026, at 16:00 IST.
Discussion will cover Unaudited Financial Results for Q3 and 9M ended December 31, 2025.
Management participants include CMD Mark Saldanha and CFO Jitendra Sharma.
Universal dial-in numbers provided: +91 22 6280 1384 and +91 22 7115 8285.
The call is hosted by DAM Capital Advisors Ltd with international toll-free options for UK, USA, HK, and Singapore.

💡 Investors should monitor the financial results release prior to the call and use the session to gain insights into management's outlook on margins and growth.

Marksans Pharma Submits SEBI Compliance Certificate for Quarter Ended Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 13 Jan 2026, 03:34 PM

Marksans Pharma Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The document, issued by Bigshare Services Private Limited, confirms the processing of dematerialization requests for the quarter ended December 31, 2025. It verifies that physical share certificates were mutilated and cancelled within the mandated 15-day timeframe. This is a standard regulatory filing ensuring the accuracy of the company's shareholding records.

Compliance certificate submitted for the quarter ended December 31, 2025.
Registrar and Transfer Agent (RTA), Bigshare Services, confirmed all dematerialization requests were processed.
Security certificates were mutilated and cancelled within 15 days of receipt as per SEBI norms.
Confirms that the name of the depositories has been substituted in the register of members as the registered owner.

💡 No action is required as this is a routine regulatory filing. Investors should continue to monitor the company's operational performance and upcoming financial results.

Marksans Pharma to Close Trading Window from January 1, 2026, for Q3 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 26 Dec 2025, 11:56 AM

Marksans Pharma Limited has announced the closure of its trading window starting January 1, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations. The closure is intended for designated persons and their immediate relatives ahead of the declaration of unaudited financial results for the quarter ending December 31, 2025. The window will remain closed until 48 hours after the results are officially announced. The specific date for the board meeting to approve these results will be communicated separately.

Trading window closure effective from Thursday, January 1, 2026.
Closure pertains to the financial results for the quarter ending December 31, 2025.
Window will reopen 48 hours after the declaration of the unaudited financial results.
Restriction applies to all designated persons and their immediate relatives as per SEBI norms.

💡 This is a routine regulatory announcement with no direct impact on stock valuation; investors should monitor for the upcoming Q3 result date for fundamental performance updates.

View All MARKSANS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The US and North America segment grew 28.8% YoY in H1 FY26, reaching INR 714.8 Cr. The OTC segment overall has shown significant growth, crossing the INR 2,000 Cr revenue mark in FY25, representing a 4.6x growth since 2017. UK and EU formulation recorded revenue of INR 245 Cr in Q2 FY26, while Australia and New Zealand recorded INR 61.3 Cr.

Geographic Revenue Split

As of H1 FY26, the US and North America market is the largest contributor at 53% (INR 714.8 Cr), followed by the UK and EU market at 34% (INR 449 Cr). Australia and New Zealand and the Rest of the World (RoW) contribute the remaining 13%.

Profitability Margins

Gross margins stood at 57.2% in Q2 FY26, a decline of 258 bps YoY from 59.7% due to product mix and pricing pressure in the UK. Net Profit Margin for Q2 FY26 was 13.4%, down 161 bps YoY. For FY25, the consolidated Net Profit margin was 14.59%.

EBITDA Margin

EBITDA margin for Q2 FY26 was 20.1%, a decrease of 108 bps YoY but an improvement of 391 bps QoQ due to operating leverage. H1 FY26 EBITDA margin was 18.2%, down 318 bps YoY, reflecting higher employee expenses at the newly acquired Unit 2 and elevated freight costs.

Capital Expenditure

The company is doubling its low-cost manufacturing capacity in India from 8 billion to 16 billion units. Total manufacturing capacity has already increased from 6 billion units p.a. in 2017 to 26 billion units p.a. following the acquisition of the Teva facility in Goa.

Credit Rating & Borrowing

Long-term bank facilities (INR 135 Cr) were upgraded to CARE AA-; Stable from CARE A+; Positive in October 2025. Short-term bank facilities (INR 120.75 Cr) were reaffirmed at CARE A1+. The company maintains a comfortable solvency position with an overall gearing of 0.12x as of March 31, 2024.

⚙️ Operational Drivers

Raw Materials

Specific API names are not disclosed, but Cost of Goods Sold (COGS) represented 43.6% of total revenue in FY25, amounting to INR 1,143.74 Cr, an increase of 10.17% YoY.

Capacity Expansion

Current total manufacturing capacity is 26 billion units p.a. Planned expansion involves doubling the India-based low-cost capacity from 8 billion to 16 billion units to support the goal of reaching INR 3,000 Cr revenue.

Raw Material Costs

Raw material costs (COGS) were INR 1,143.74 Cr in FY25. While COGS increased by 10.17%, this was lower than the 20.46% revenue growth, indicating efficient procurement or better product mix during that period.

Manufacturing Efficiency

Operating leverage is a key driver, with EBITDA margins improving sequentially by 391 bps in Q2 FY26 as the Teva facility (Unit 2) ramps up production and revenue grows.

Logistics & Distribution

Freight costs are noted as 'elevated' due to the Red Sea crisis, impacting the PBILDT margins in recent quarters.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

The company aims to reach INR 3,000 Cr revenue by doubling US/North America revenue and becoming a top 5 private label OTC company in that region. Strategy includes doubling India manufacturing capacity, expanding into Germany (organic operations), and launching new products in digestive and pain management segments.

Products & Services

Tablets (plain, enteric-coated, film-coated), hard capsules, soft gelatin capsules, oral liquids, and ointments primarily for the OTC and prescription markets.

Brand Portfolio

Bells, Sons & Co, Relonchem, Time Cap Laboratories, and Nova Pharmaceuticals.

New Products/Services

New product launches in digestive and pain management segments drove a 27% YoY revenue increase in the US market during Q2 FY26. The company maintains a healthy pipeline of ANDAs.

Market Expansion

Plans to start organic operations in Germany, requiring investment in personnel and regulatory filings. It also recently acquired Access Healthcare in Dubai to expand its footprint.

Market Share & Ranking

Aims to become one of the top 5 private label OTC companies in the US and North America region.

Strategic Alliances

Strategic focus on acquisitions such as the Teva Pharma India facility and partnerships in key global markets to widen the portfolio.

🌍 External Factors

Industry Trends

The pharmaceutical industry is seeing a shift toward OTC segments; Marksans' OTC revenue grew 4.6x since 2017 to INR 2,066 Cr. The industry remains highly regulated by bodies like the US FDA and UK MHRA.

Competitive Landscape

Faces competition from established players in new geographic markets; mitigated by R&D and a diversified product portfolio of 1,500+ SKUs.

Competitive Moat

Moat is built on low-cost manufacturing at scale (26 bn units), a diversified geographic presence (US, UK, Australia), and a strong track record of successful acquisitions and regulatory compliance.

Macro Economic Sensitivity

The US region demonstrated resilience amid macro challenges, with revenue growing 27% YoY in Q2 FY26 despite stabilizing tariff conditions.

Consumer Behavior

Robust demand in key markets for digestive and pain management products is driving sequential revenue growth of 16% in Q2 FY26.

Geopolitical Risks

The Red Sea crisis is specifically cited as a factor elevating freight costs and impacting margins.

⚖️ Regulatory & Governance

Industry Regulations

Facilities are approved by UK MHRA, US FDA, and Australian TGA. The Goa facility recently underwent GMP audits by these authorities.

Environmental Compliance

Facilities operate in adherence to environmental norms including effluent treatment. The company is investing in green chemistry and energy-efficient systems.